LSD Depression

On Monday, June 22, 2026, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for major depressive disorder (MDD). It’s the first Phase 3 readout for the company, and for LSD. Definium Therapeutics (DFTX) — DT120 Phase 3 Emerge: Key Points The...